FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386769931> ?p ?o ?g. }

• W4386769931 abstract "Fibroblast growth factor receptor (FGFR) gene family alterations are found in several cancers, indicating their importance as potential therapeutic targets. The FGFR-tyrosine kinase inhibitor (TKI) pemigatinib has been introduced in the treatment of advanced cholangiocarcinoma and more recently for relapsed or refractory myeloid/lymphoid neoplasms with FGFR2 and FGFR1 rearrangements, respectively. Several clinical trials are currently investigating the possible combination of pemigatinib with immunotherapy. In this study, we analyzed the biological and molecular effects of pemigatinib on different cancer cell models (lung, bladder, and gastric), which are currently objective of clinical trial investigations.NCI-H1581 lung, KATO III gastric and RT-112 bladder cancer cell lines were evaluated for FGFR expression by qRT-PCR and Western blot. Cell lines were treated with Pem and then characterized for cell proliferation, apoptosis, production of intracellular reactive oxygen species (ROS), and induction of senescence. The expression of microRNAs with tumor suppressor functions was analyzed by qRT-PCR, while modulation of the proteins coded by their target genes was evaluated by Western blot and mRNA. Descriptive statistics was used to analyze the various data and student's t test to compare the analysis of two groups.Pemigatinib exposure triggered distinct signaling pathways and reduced the proliferative ability of all cancer cells, inducing G1 phase cell cycle arrest and strong intracellular stress resulting in ROS production, senescence and apoptosis. Pemigatinib treatment also caused the upregulation of microRNAs (miR-133b, miR-139, miR-186, miR-195) with tumor suppressor functions, along with the downregulation of validated protein targets with oncogenic roles (c-Myc, c-MET, CDK6, EGFR).These results contribute to clarifying the biological effects and molecular mechanisms mediated by the anti-FGFR TKI pemigatinib in distinct tumor settings and support its exploitation for combined therapies." @default.
• W4386769931 created "2023-09-16" @default.
• W4386769931 creator A5019444838 @default.
• W4386769931 creator A5037100565 @default.
• W4386769931 creator A5048517130 @default.
• W4386769931 creator A5057342286 @default.
• W4386769931 creator A5065468471 @default.
• W4386769931 creator A5067780934 @default.
• W4386769931 creator A5069311489 @default.
• W4386769931 creator A5073477327 @default.
• W4386769931 creator A5075605378 @default.
• W4386769931 creator A5077292803 @default.
• W4386769931 creator A5077736286 @default.
• W4386769931 creator A5085420813 @default.
• W4386769931 creator A5092090169 @default.
• W4386769931 date "2023-09-15" @default.
• W4386769931 modified "2023-09-27" @default.
• W4386769931 title "Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs" @default.
• W4386769931 cites W1978776093 @default.
• W4386769931 cites W2007223616 @default.
• W4386769931 cites W2037373653 @default.
• W4386769931 cites W2050980456 @default.
• W4386769931 cites W2054946171 @default.
• W4386769931 cites W2056983875 @default.
• W4386769931 cites W2124451085 @default.
• W4386769931 cites W2126525177 @default.
• W4386769931 cites W2129566355 @default.
• W4386769931 cites W2138617860 @default.
• W4386769931 cites W2230916201 @default.
• W4386769931 cites W2463080053 @default.
• W4386769931 cites W2476907789 @default.
• W4386769931 cites W2550902247 @default.
• W4386769931 cites W2742928474 @default.
• W4386769931 cites W2744466715 @default.
• W4386769931 cites W2752860657 @default.
• W4386769931 cites W2793353518 @default.
• W4386769931 cites W2801774047 @default.
• W4386769931 cites W2804659417 @default.
• W4386769931 cites W2807032285 @default.
• W4386769931 cites W2884126108 @default.
• W4386769931 cites W2889873218 @default.
• W4386769931 cites W2895962125 @default.
• W4386769931 cites W2901828997 @default.
• W4386769931 cites W2925017918 @default.
• W4386769931 cites W2929491112 @default.
• W4386769931 cites W2944145978 @default.
• W4386769931 cites W2963091977 @default.
• W4386769931 cites W2981062729 @default.
• W4386769931 cites W2984955289 @default.
• W4386769931 cites W2996643695 @default.
• W4386769931 cites W3007294163 @default.
• W4386769931 cites W3010944770 @default.
• W4386769931 cites W3016732114 @default.
• W4386769931 cites W3025716972 @default.
• W4386769931 cites W3032673000 @default.
• W4386769931 cites W3037755386 @default.
• W4386769931 cites W3045772015 @default.
• W4386769931 cites W3081516820 @default.
• W4386769931 cites W3082375983 @default.
• W4386769931 cites W3082979654 @default.
• W4386769931 cites W3085853688 @default.
• W4386769931 cites W3091861153 @default.
• W4386769931 cites W3091935662 @default.
• W4386769931 cites W3096583666 @default.
• W4386769931 cites W3107763051 @default.
• W4386769931 cites W3108774824 @default.
• W4386769931 cites W3111344382 @default.
• W4386769931 cites W3126629350 @default.
• W4386769931 cites W3127785161 @default.
• W4386769931 cites W3128610255 @default.
• W4386769931 cites W3174271555 @default.
• W4386769931 cites W3178390673 @default.
• W4386769931 cites W3207086895 @default.
• W4386769931 cites W3214615590 @default.
• W4386769931 cites W3216467874 @default.
• W4386769931 cites W4210364498 @default.
• W4386769931 cites W4220723714 @default.
• W4386769931 cites W4221116767 @default.
• W4386769931 cites W4224871294 @default.
• W4386769931 cites W4290804243 @default.
• W4386769931 cites W4296129731 @default.
• W4386769931 cites W4303437712 @default.
• W4386769931 cites W4304014509 @default.
• W4386769931 cites W4304892036 @default.
• W4386769931 cites W4307984032 @default.
• W4386769931 cites W4311328502 @default.
• W4386769931 cites W4360951491 @default.
• W4386769931 cites W4362460401 @default.
• W4386769931 doi "https://doi.org/10.1186/s12967-023-04450-7" @default.
• W4386769931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37715207" @default.
• W4386769931 hasPublicationYear "2023" @default.
• W4386769931 type Work @default.
• W4386769931 citedByCount "0" @default.
• W4386769931 crossrefType "journal-article" @default.
• W4386769931 hasAuthorship W4386769931A5019444838 @default.
• W4386769931 hasAuthorship W4386769931A5037100565 @default.
• W4386769931 hasAuthorship W4386769931A5048517130 @default.
• W4386769931 hasAuthorship W4386769931A5057342286 @default.
• W4386769931 hasAuthorship W4386769931A5065468471 @default.
• W4386769931 hasAuthorship W4386769931A5067780934 @default.

• next